Navigation Links
Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
Date:3/18/2008

CAMBRIDGE, Mass., March 18 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that it has completed its first clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase I single ascending dose, double blind placebo controlled randomized study involved 56 healthy volunteers who received the drug in eight escalating dose cohorts. All doses were safe and well tolerated, and there were no serious adverse events. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose related pharmacokinetics were observed. The Company plans to initiate its first repeat dose study in multiple sclerosis patients in Q2/2008.

"We are pleased to see that PI-2301 was well tolerated and that this trial has provided evidence of single dose priming of healthy subjects. This effect is important as repeated doses in multiple sclerosis patients should lead to therapeutic immune modulation," stated Thomas P. Mathers, President and CEO of Peptimmune. "We have designed PI-2301 to maximize the therapeutic benefit of a proven, safe compound class in multiple sclerosis as well as increasing patients' convenience."

PI-2301 is a second generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the pathogenic autoimmune response in certain diseases. PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and in pre- clinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in pre-clinical models of autoimmune diseases where immune modulation may be effe
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
3. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
4. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
5. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
6. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
7. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
8. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
9. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...cal Incorporated (Nasdaq: VICL ) announced today...rom Merck & Co., Inc. based on Merck,s planned...stigational plasmid DNA (pDNA) cancer vaccine. The...livery technology and encodes human telomerase rev...f separate license agreement. , , "The brea...
(Date:11/28/2008)...- Eli Lilly and Company,(NYSE: LLY ) has withdr...rom,the U.S. Food and Drug Administration (FDA) f...t of chronic pain. Lilly plans to resubmit the app...rom a recently completed positive study,in chroni...cision does not affect duloxetine,s FDA-approved i...
(Date:11/26/2008)...KLIN, Mass., Nov. 26 PLC...d today that it has received full approval from th...U.S. pivotal trial to study the effectiveness of t... therapy in the prevention of Contrast-Induced Nep...LC,s request to expand their investigation from th...
(Date:11/25/2008)...re/ -- Proteolix, Inc., a,leader in the discovery...,protein degradation pathways in cancer and autoi...o ongoing Phase 2 clinical trials of carfilzomib i...ing 50th Annual Meeting of the,American Society o... new class,of specific proteasome inhibitors and ...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3LI COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging 8527 1LI COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging 8527 2DFG continues to strengthen biodiversity research 5543 1DFG continues to strengthen biodiversity research 5543 2Innovative strategies for war wounded 5538 1Innovative strategies for war wounded 5538 2Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 1Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 2Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 3
...lso Support Drug,s Efficacy at Improving Glycemic ...ications, CHICAGO, Ill., June 23, 2007 /PRNewswire...mercialization partner S2 Therapeutics,Inc., repo...trial,supporting the overall and cardiovascular sa...of bromocriptine mesylate) in subjects,with type 2...
...R CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--Gi...that Study 103, a,Phase III clinical trial evaluat...R) (tenofovir disoproxil fumarate or tenofovir,DF)...itis B virus,(HBV) infection, met its primary effi...ferior to the company,s once-daily antiviral,drug ...
Other Medicine Technology:Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 2Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 3Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
(Date:12/1/2008)... Dec. 1 Actavis Group, the interna...unced that it has received approval from the U.S. ... Hydrochloride extended-release tablets (XL) 150mg... , Bupropion Hydrochloride extended-release ...h, are the generic equivalent of Wellbutrin XL(R) ...
(Date:12/1/2008)... , Ideas from U-M physician include economical... A bottle of cologne, a... and easy gifts to buy and wrap for the upcoming h...ng more healthy and beneficial to a loved one? Why...healthy around the holidays can be challenging, an...
(Date:12/1/2008)...PRNewswire/ -- Resurrection Health Care has been r...lthcare by Modern Healthcare,magazine. The nation...ing,homes, retirement communities, home health se...ices throughout the Chicago area. , Modern ...s health care,organizations nationwide that enabl...
(Date:12/1/2008)... 1 Prior generations often shared,...ents -- typically because,seniors didn,t live far...h,life expectancy having increased by an average ...mbered by health care concerns, which may make old...emselves. In the recently published,Evercare(R) S...
Breaking Medicine News(10 mins):Health News:Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S. 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:Resurrection Health Care Named One of Nation's 'Best Places to Work in Healthcare' 2Health News:Take Time to Care for the Caregiver 2
... the brain of youngsters, says a study, which stre... can do to them. // Thomas Heffernan, a psychologi...llege students for the research presented at the B...s annual conference in York, reported the online e...
...r still remains the best way to ensure patient s...ring the 85th General Session of the International...the University of California-Irvine presented two ...approaches to oral cancer detection, diagnostic sc...
...m Aberdeen University are on the brink of another ...s of lives,// by an early diagnosis of cancer, Alz...ther disorders. A prototype of an MRI scanner has...ferent images, compared to one image from current ...
...oon urged governments to join the anti-tuberculosi...n coming years as// the disease has become extreme...ng the importance of World TB Day on Saturday. The...tly reported about the rise in the extensively dru...
Other Medicine News:Health News:Novel Methods in Diagnosing Oral Cancer 2Health News:Breakthrough in MRI Scanning in the Near Future 2
15" overall length, 9" handle.
Gimmi Yasargil Aneurysm-Vessel-Clips
Yasargil Phynox Aneurysm Clips Standard
EDM Ventricular Drainage Kit, with Drip Chamber with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in
Medicine Products: